These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 22492244)
1. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Palmroth J; Merikukka M; Paavonen J; Apter D; Eriksson T; Natunen K; Dubin G; Lehtinen M Int J Cancer; 2012 Dec; 131(12):2832-8. PubMed ID: 22492244 [TBL] [Abstract][Full Text] [Related]
2. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ; MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109 [TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565 [TBL] [Abstract][Full Text] [Related]
4. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Perez G; Lazcano-Ponce E; Hernandez-Avila M; García PJ; Muñoz N; Villa LL; Bryan J; Taddeo FJ; Lu S; Esser MT; Vuocolo S; Sattler C; Barr E Int J Cancer; 2008 Mar; 122(6):1311-8. PubMed ID: 18000825 [TBL] [Abstract][Full Text] [Related]
5. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299 [TBL] [Abstract][Full Text] [Related]
6. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years. Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767 [TBL] [Abstract][Full Text] [Related]
7. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV). Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G; J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076 [TBL] [Abstract][Full Text] [Related]
9. Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study. Namujju PB; Pajunen E; Simen-Kapeu A; Hedman L; Merikukka M; Surcel HM; Kirnbauer R; Apter D; Paavonen J; Hedman K; Lehtinen M BMC Res Notes; 2014 Jul; 7():445. PubMed ID: 25011477 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial. Hu S; Xu X; Zhu F; Hong Y; Hu Y; Zhang X; Pan Q; Zhang W; Zhang C; Yang X; Yu J; Zhu J; Zhu Y; Chen F; Zhao S; Karkada N; Tang H; Bi D; Struyf F; Zhao F Hum Vaccin Immunother; 2021 Apr; 17(4):955-964. PubMed ID: 33180670 [TBL] [Abstract][Full Text] [Related]
11. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Merikukka M; Kaasila M; Namujju PB; Palmroth J; Kirnbauer R; Paavonen J; Surcel HM; Lehtinen M Int J Cancer; 2011 Mar; 128(5):1114-9. PubMed ID: 20839258 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311 [TBL] [Abstract][Full Text] [Related]
13. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Lehtinen M; Idänpään-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046 [TBL] [Abstract][Full Text] [Related]
14. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Paavonen J; Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868 [TBL] [Abstract][Full Text] [Related]
16. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739 [TBL] [Abstract][Full Text] [Related]
17. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279 [TBL] [Abstract][Full Text] [Related]
18. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149 [TBL] [Abstract][Full Text] [Related]
19. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663 [TBL] [Abstract][Full Text] [Related]
20. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Demarteau N; Van Kriekinge G; Simon P Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]